News

Fierce Pharma11h
FDA advisors unanimously snub Pfizer's Talzenna in broader prostate cancer population
In a somber end to an FDA advisory committee’s two-day scouring of multiple drugmakers’ oncology data, Pfizer’s pitch to ...
BioSpace12h
Pfizer’s Talzenna Expansion Fails To Earn FDA Advisory Committee’s Support
The FDA’s independent advisors found Pfizer’s data lacked the precision needed to establish the efficacy of Talzenna in ...
BioPharma Dive10h
FDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne study
An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K.
Pfizer bid to expand Talzenna use in prostate cancer questioned by FDA panel
A U.S. FDA panel of independent experts beat back an effort by Pfizer (NYSE:PFE) to expand the patient population for its ...
pharmaphorum16h
Mixed outcomes for pharma in big week for FDA adcomms
For J&J, there was a positive outcome as the Oncologic Drugs Advisory Committee (ODAC) voted six to two in favour of approval ...
Fierce Pharma6d
Weighing approval bids from J&J, Pfizer and Roche, FDA scrutinizes data ahead of adcomm
One possible explanation for the gap is the availability of highly efficacious CAR-T therapies in the U.S. and Europe serving ...
RTE Online23d
Pfizer misses revenue expectations, sees $1.7 billion more in cost savings
Pfizer said today it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research operations and reported lower first-quarter revenue due to declining sales of ...